Fate Therapeutics Announces Treatment of First Patient in Landmark Phase I Clinical Trial of FT819, the First-Ever iPSC-Derived CAR T-Cell Therapy

Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.